Treatment of Childhood Acute Lymphoblastic Leukemia

• Status: Terminated
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia therapy, to attain long-term control of the disease and to hopefully eradicate it.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Boston Children's Hospital; Boston Children’s Hospital
• Treatments: Asparaginase; Dexrazoxane; Doxorubicin; Razoxane

Criteria

Inclusion Criteria:

• Acute lymphoblastic leukemia, excluding known mature B-cell ALL

• < 18 years of age

• Patients who are leukopheresed or exchanged are eligible for study only after completion of the pheresis or exchange transfusion

• Absence of a t(8,14) (q24; q32), t (8,22), t(2,8)

• Total bilirubin < 1.4mg/dl

Exclusion Criteria:

• Known HIV positive

• Prior steroid therapy within 30 days of diagnosis

• Septic shock

• Ongoing intracranial hemorrhage

• Clinical evidence of CNS or lung leukostasis